Company intelligence / Profile preview

SupremeCure Pharma

Shanghai, Shanghai, China

Ownership: Private
Development stage: Other

Overview

SupremeCure Pharma is a clinical-stage biopharmaceutical company dedicated to discovering and developing innovative small molecule therapeutics targeting deubiquitinating enzymes (DUBs). The company leverages its proprietary platform to address unmet medical needs in oncology and immunology, with a primary focus on synthetic lethality and protein homeostasis. Its lead candidate, SC-001, is a potent and selective USP1 inhibitor currently being evaluated in Phase 1 clinical trials for the treatment of advanced solid tumors, particularly those with BRCA mutations. SupremeCure aims to provide next-generation precision medicines by modulating the ubiquitin-proteasome system.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

SC-43

Beyond the preview

Go deeper on SupremeCure Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SupremeCure Pharma.

Explore the full profile